InvestorsHub Logo
icon url

lightrock

06/30/21 11:31 AM

#39539 RE: Bcmorano #39538

My understanding is we can't use the 48.6 because that's SEER data, and we're talking about what actually happened between the test and control arms, etc.,

Maybe it can come out in a scientific paper why the entire population of the study did so well.

Maybe it could say something like "keytruda" was later applied to just about everyone also. That sort of thing. There is no way to know until the papers come out.

The study protocol does not preclude ANY further treatment by ANY means.

Clear ?

Before we got any data whatsoever, the ONLY thing in the world to compare the trail run length to was SEER data.

The actual race is between test and control groups
icon url

lightrock

06/30/21 12:04 PM

#39549 RE: Bcmorano #39538

My bad, that was the 5 year actual, apparently

That's almost exactly the differential what we wanted to see at 3 year

and the 5-year survival advantage was 14.1% (62.7% vs 48.6%) for the pre-defined population receiving no chemotherapy.